BrainSpec
BrainSpec is a Boston-based health technology company building MR Spectroscopy analysis software that enables non-invasive, biochemical "virtual biopsy" diagnosis and monitoring of brain disorders, currently in pre-commercial stage pending FDA clearance.
- Company typePrivate
- Founded2015
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What BrainSpec does
BrainSpec is a Boston-based health technology company developing software for the analysis of Magnetic Resonance Spectroscopy (MRS) data, with the goal of enabling non-invasive "virtual biopsies" of brain tissue. The platform processes MRS signals to identify and quantify neurometabolites such as N-Acetylaspartate, Choline, Creatine, Glutamate, Glutamine, Myo-Inositol, Lactate, and 2-Hydroxyglutarate, producing chemical fingerprints that can distinguish disease-specific molecular signatures in conditions including brain tumors, traumatic brain injury, Alzheimer's disease, multiple sclerosis, Parkinson's disease, epilepsy, schizophrenia, and hypoxic ischemic encephalopathy. The technology runs on standard MRI hardware already deployed in hospitals, and is positioned to detect biochemical changes before structural changes become visible on conventional MRI.
The company was formed at a brainstorming session at the iHub at Brigham and Women's Hospital, with collaborators from Massachusetts General Hospital, and has since established research relationships with Dana-Farber Cancer Institute, Mayo Clinic, and Swedish Medical Group. The product is currently labeled "RESEARCH USE ONLY. PENDING FDA CLEARANCE," and no pricing or commercial customers have been disclosed. The planned business model is a recurring subscription for the BrainSpec MRS Analysis Platform, to be activated upon regulatory clearance. CEO and co-founder Alexandra Zimmerman leads a 1-10 person team. Disclosed funding to date totals approximately $1.86M across rounds from 2016-2020, with DCVC, Tuesday Capital, Techstars, Right Side Capital Management, and Dorm Room Fund among past investors.
BrainSpec firmographics
Firmographics- Name
- BrainSpec
- Legal name
- BrainSpec Inc.
- Website
- https://brainspecmed.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BrainSpec is a Boston-based health technology company building MR Spectroscopy analysis software that enables non-invasive, biochemical "virtual biopsy" diagnosis and monitoring of brain disorders, currently in pre-commercial stage pending FDA clearance.
- Ownership category
- akta.pro rank
BrainSpec industry classification
Industry- Product category
- Neuroimaging Software
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Neurodiagnostic Centers (EEG/EMG/NCS) (HLAFAKAK)
- akta.pro secondary industries
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE), General Neurology (HLAKAIAA)
Keywords
Where BrainSpec is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
BrainSpec business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- MRS Software Solutions: The company is developing software solutions for MRS data analysis. Currently labeled as 'RESEARCH USE ONLY. PENDING FDA CLEARANCE', indicating they are in pre-commercial development phase with future plans for clinical commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
BrainSpec product offering
Product offeringCore offering
BrainSpec develops a software platform that analyzes Magnetic Resonance Spectroscopy (MRS) data to provide non-invasive biochemical characterization of brain tissue. The platform processes neurometabolite data (such as N-Acetylaspartate, Choline, Creatine, Glutamate, and 2-Hydroxyglutarate) to generate chemical fingerprints that aid in the diagnosis and monitoring of neurological conditions including brain tumors, Alzheimer's disease, multiple sclerosis, Parkinson's disease, traumatic brain injury, epilepsy, schizophrenia, and hypoxic ischemic encephalopathy. The product is currently labeled "Research Use Only. Pending FDA Clearance."
Product overview
BrainSpec offers a single unified software platform that enhances Magnetic Resonance Spectroscopy (MRS) data analysis for neuroimaging. The platform processes MRS data to provide chemical fingerprints unique to tissues and pathologies, enabling clinicians and researchers to perform virtual biopsies. The core BrainSpec MRS Analysis Platform is complemented by demo request, feedback, and waitlist functionality accessible through Google Forms, allowing users to engage with the product team. The company is currently in research use only status with pending FDA clearance.
Differentiator
Problem solved
Functional benefit
Products and services
- BrainSpec MRS Analysis Platform
Quantifiable outcome
- MR Spectroscopy detects biochemical changes before structural changes occur in the brain
Companies that use BrainSpec
Customer profileSegments8 records
Ideal customer profiles3 records
BrainSpec technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
BrainSpec partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Brigham and Women's Hospital (iHub)coreThe team was formed at a brainstorming session hosted by the iHub at Brigham and Women's Hospital, designed to help clinicians and researchers bring their ideas into reality. Brigham and Women's is a key research collaborator for BrainSpec's MRS technology development.
- Massachusetts General HospitalcoreCollaborating institution providing clinical expertise. Experienced radiologists, oncologists, neurologists and neurosurgeons at Massachusetts General Hospital contribute to the development and validation of BrainSpec's MRS technology.
- Dana-Farber Cancer InstitutecoreResearch site for BrainSpec's neuro-oncology applications. Dana-Farber researchers collaborate on brain tumor MRS analysis and virtual biopsy development.
- Mayo CliniccoreResearch site for clinical validation of MRS technology. Mayo Clinic contributes to multi-center validation studies for various neurological conditions.
- Swedish Medical GroupminorResearch site contributing to BrainSpec's clinical validation efforts in neurological conditions.
Recent moves4 records
Expansion highlights5 records
BrainSpec competitors and assessment
Company assessmentDirect peers
- icometrix: icometrix develops AI-based software for quantitative brain MRI analysis, with FDA-cleared products for MS, dementia, and TBI. Like BrainSpec, it sells neuroimaging software to hospitals and radiology practices and pursues disease-monitoring indications, making it the most direct peer.
- Olea Medical: Olea Medical provides advanced MRI and CT post-processing software for neurological and oncological applications. It competes in the same neurodiagnostic analytics space, offering perfusion and diffusion tools similar in spirit to BrainSpec's MRS analytics.
- Quibim: Quibim builds AI-powered medical imaging biomarkers across oncology and neurology, sold to hospitals and pharma for trial endpoints. Its biomarker-as-a-service approach parallels BrainSpec's virtual biopsy positioning.
Emerging players
- Cercare Medical: Cercare Medical develops AI neuroimaging biomarkers for stroke and oncology using perfusion and diffusion MRI. It overlaps with BrainSpec in delivering quantitative neuro biomarker software to clinical and research customers.
- CorTechs Labs (NeuroQuant): CorTechs Labs' NeuroQuant is an FDA-cleared brain volumetrics tool used in MS and dementia workflows. It addresses similar neurological use cases via MRI post-processing and competes for the same hospital neuroimaging software budget.
- Subtle Medical: Subtle Medical applies AI to accelerate and improve MRI acquisition. While focused on image acquisition rather than spectroscopy analytics, it targets the same hospital radiology customers with AI-enabled MRI software.
Broad incumbents
- Brainlab: Brainlab offers a broad portfolio of neurosurgery, radiation oncology, and imaging software used in hospitals. While much larger, it overlaps with BrainSpec in selling advanced neuro imaging software to academic medical centers.
- Siemens Healthineers: Siemens Healthineers is a leading MRI OEM and developer of advanced post-processing applications including spectroscopy tools. It is the dominant incumbent against which standalone MRS analytics vendors must compete.
- GE HealthCare: GE HealthCare manufactures MRI systems and bundles advanced imaging applications. Its installed base and OEM leverage pose a structural competitive threat to independent neuroimaging analytics providers like BrainSpec.
- Philips Healthcare: Philips Healthcare sells MRI scanners and integrated clinical informatics, including neurology-focused imaging software. Its OEM position and global hospital relationships make it a key incumbent to track for any neuroimaging analytics entrant.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
BrainSpec social profiles
Digital presenceBrainSpec financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrainSpec leadership team
Management profileNumber of profiles
Profiles1 record
BrainSpec funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrainSpec M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrainSpec
What does BrainSpec do?
BrainSpec develops a software platform that analyzes Magnetic Resonance Spectroscopy (MRS) data to provide non-invasive biochemical characterization of brain tissue. The platform processes neurometabolite data (such as N-Acetylaspartate, Choline, Creatine, Glutamate, and 2-Hydroxyglutarate) to generate chemical fingerprints that aid in the diagnosis and monitoring of neurological conditions including brain tumors, Alzheimer's disease, multiple sclerosis, Parkinson's disease, traumatic brain injury, epilepsy, schizophrenia, and hypoxic ischemic encephalopathy. The product is currently labeled "Research Use Only. Pending FDA Clearance."
Is BrainSpec a public or private company?
BrainSpec is a private company. It is classified as venture growth investor backed and is currently operating.
When was BrainSpec founded?
BrainSpec was founded in 2015. It employs 1 to 10 people.
Where is BrainSpec based?
BrainSpec is headquartered in Boston, United States, in the North America region.
How does BrainSpec make money?
One revenue line is on record: MRS Software Solutions.
Who are BrainSpec's main competitors?
Direct peers on record are icometrix, Olea Medical and Quibim. Emerging players are Cercare Medical, CorTechs Labs (NeuroQuant) and Subtle Medical. Broad incumbents are Brainlab, Siemens Healthineers, GE HealthCare and Philips Healthcare.
Does BrainSpec have an API?
No public API is recorded for BrainSpec.
What industry is BrainSpec in?
BrainSpec's product category is Neuroimaging Software. Its primary akta.pro industry code is HLAFAKAK, Neurodiagnostic Centers (EEG/EMG/NCS), with a secondary code of HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables). Its NAICS code is 621511 and its SIC code is 8071.